Allergan PLC (NYSE:AGN) traded down 1.4% during trading on Thursday . The company traded as low as $238.72 and last traded at $239.83, with a volume of 2,623,369 shares changing hands. The stock had previously closed at $243.27.

Several research firms recently issued reports on AGN. JPMorgan Chase & Co. restated an “overweight” rating on shares of Allergan PLC in a research report on Friday, May 13th. Credit Suisse Group AG began coverage on shares of Allergan PLC in a research report on Monday, July 25th. They set an “outperform” rating and a $327.00 price objective for the company. Zacks Investment Research cut shares of Allergan PLC from a “buy” rating to a “hold” rating in a research report on Tuesday, July 26th. Vetr cut shares of Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $283.05 price objective for the company. in a research report on Monday, August 8th. Finally, Leerink Swann set a $294.00 price objective on shares of Allergan PLC and gave the stock a “buy” rating in a research report on Monday, August 8th. Six investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $309.13.

The company’s 50-day moving average price is $248.71 and its 200 day moving average price is $249.05. The firm has a market cap of $93.57 billion and a price-to-earnings ratio of 22.50.

Allergan PLC (NYSE:AGN) last posted its earnings results on Monday, August 8th. The company reported $3.35 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.34 by $0.01. The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same period last year, the company posted $4.41 EPS. The firm’s revenue for the quarter was up 1.0% compared to the same quarter last year. Equities analysts predict that Allergan PLC will post $14.00 earnings per share for the current fiscal year.

In other Allergan PLC news, CFO Maria Teresa Hilado bought 661 shares of the company’s stock in a transaction that occurred on Thursday, June 2nd. The stock was purchased at an average price of $241.57 per share, with a total value of $159,677.77. Following the transaction, the chief financial officer now owns 11,957 shares in the company, valued at $2,888,452.49. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Other hedge funds have recently modified their holdings of the company. Eaton Vance Management increased its stake in shares of Allergan PLC by 276.7% in the fourth quarter. Eaton Vance Management now owns 793,555 shares of the company’s stock valued at $247,986,000 after buying an additional 582,890 shares during the period. State of Tennessee Treasury Department increased its stake in shares of Allergan PLC by 135.7% in the fourth quarter. State of Tennessee Treasury Department now owns 466,141 shares of the company’s stock valued at $145,669,000 after buying an additional 268,357 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Allergan PLC by 6.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,596,389 shares of the company’s stock valued at $498,895,000 after buying an additional 103,314 shares during the period. Schwab Charles Investment Management Inc. increased its stake in shares of Allergan PLC by 4.0% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 1,069,878 shares of the company’s stock valued at $334,337,000 after buying an additional 40,665 shares during the period. Finally, King Luther Capital Management Corp increased its stake in shares of Allergan PLC by 359.2% in the fourth quarter. King Luther Capital Management Corp now owns 22,125 shares of the company’s stock valued at $6,914,000 after buying an additional 17,307 shares during the period.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.